CD38 Inhibitor 78c Attenuates Pro-Inflammatory Cytokine Expression and Osteoclastogenesis in Macrophages
Cells · 2024
DOI: 10.3390/cells13231971 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von William Lory und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical and Community Health Sciences, College of Dental Medicine, Medical University of South Carolina, Charleston, SC 29425, USA. Hauptthemen laut MEDLINE: Cytokines, ADP-ribosyl Cyclase 1, Osteogenesis, Macrophages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDCR NIH HHS, National Institute of Health, Center for Healthy Aging, Medical University of South Carolina.
Abstract (Originalsprache)
CD38, a nicotinamide adenine dinucleotide (NAD+) glycohydrolase, increases during infection or inflammation. Therefore, we aimed to evaluate the effects of a CD38 inhibitor (78c) on NAD+ levels, IL-1β, IL-6, TNF-α cytokine expressions, and osteoclastogenesis. The results show that treatment with 78c on murine BMMs dose-dependently reduced CD38, reversed the decline of NAD+, and inhibited IL-1β, IL-6, and TNF-α pro-inflammatory cytokine levels induced by oral pathogen Porphyromonas gingivalis (Pg) or Aggregatibacter actinomycetemcomitans (Aa) or by advanced glycation end products (AGEs). Additionally, treatment with 78c dose-dependently suppressed osteoclastogenesis and bone resorption induced by RANKL. Treatment with 78c suppressed CD38, nuclear factor kappa-B (NF-κB), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinases (MAPKs) induced by Pg, Aa, or AGEs, and suppressed podosome components (PI3K, Pyk2, Src, F-actin, integrins, paxillin, and talin) induced by RANKL. These results from our studies support the finding that the inhibition of CD38 by 78c is a promising therapeutic strategy to treat inflammatory bone loss diseases. However, treatment with a CD38 shRNA only significantly reduced IL-1β, IL-6, and TNF-α pro-inflammatory cytokine levels induced by AGEs. Compared with controls, it had limited effects on cytokine levels induced by Pg or Aa. Treatment with the CD38 shRNA enhanced RANKL-induced osteoclastogenesis, suggesting that 78c has some off-target effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical and Community Health Sciences, College of Dental Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
- Department of Endocrinology, College of Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.
ORCID-Profile: Nityananda Chowdhury, Subramanya Pandruvada, Özlem Yilmaz, Hong Yu
Förderung
- NIDCR NIH HHS
- National Institute of Health
- Center for Healthy Aging, Medical University of South Carolina
- NCATS NIH HHS
- National Institutes of Health
- Medical University of South Carolina, Center for Healthy Aging
Zitieren
APA
Lory, W., Chowdhury, N., Wellslager, B., Pandruvada, S., Huang, Y., Yilmaz, Ö., & Yu, H. (2024). CD38 Inhibitor 78c Attenuates Pro-Inflammatory Cytokine Expression and Osteoclastogenesis in Macrophages. Cells. https://doi.org/10.3390/cells13231971
Vancouver
Lory W, Chowdhury N, Wellslager B, Pandruvada S, Huang Y, Yilmaz Ö, et al. CD38 Inhibitor 78c Attenuates Pro-Inflammatory Cytokine Expression and Osteoclastogenesis in Macrophages. Cells. 2024. doi:10.3390/cells13231971
BibTeX
@article{Lory2024,
author = {Lory, William and Chowdhury, Nityananda and Wellslager, Bridgette and Pandruvada, Subramanya and Huang, Yan and Yilmaz, Özlem and Yu, Hong},
title = {CD38 Inhibitor 78c Attenuates Pro-Inflammatory Cytokine Expression and Osteoclastogenesis in Macrophages},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13231971}
}
EUVIMED